Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

77.47 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist

Price and Volume

Volume	0
Open	77.47
Bid (Size)	53.00 (100)
Ask (Size)	100.00 (100)
Prev. Close	77.47
Today's Range	77.47 - 77.47
52wk Range	23.18 - 123.75
Shares Outstanding	11,834,361
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

Via The Motley Fool

Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal

April 07, 2026

In a move that signals a significant consolidation within the rare endocrine disease market, Neurocrine Biosciences (NASDAQ: NBIX) announced on April 6, 2026, that it has entered into a definitive...

Via MarketMinute

Performance

YTD	-7.2%	-7.2%
1 Month	-13.8%	-13.8%
3 Month	-7.7%	-7.7%
6 Month	+33.6%	+33.6%
1 Year	+142.2%	+142.2%

More News

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

January 09, 2026

From Bright Minds Biosciences

Via GlobeNewswire

The market is filled with gapping stocks in Wednesday's session. ↗

January 07, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

January 06, 2026

Via Chartmill

Why Did DRUG Stock Rocket 51% Today? ↗

January 06, 2026

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 06, 2026

Via Chartmill

Why Bright Minds Biosciences Stock Topped the Market on Monday ↗

November 17, 2025

Via The Motley Fool

Large Patient Population Is Key Driver For Bright Minds' Growth ↗

September 08, 2025

Via Benzinga

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗

May 07, 2025

Via Benzinga

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

March 04, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

February 24, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Biotechs on the Brink: 2 Stocks With Huge Potential

February 14, 2025

Via MarketBeat

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

January 23, 2025

Via Benzinga

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

January 07, 2025

From Bright Minds Biosciences

Via GlobeNewswire

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

November 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗

November 13, 2024

Via The Motley Fool

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

November 04, 2024

From Bright Minds Biosciences

Via GlobeNewswire

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗

November 04, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock? ↗

October 21, 2024

Via Benzinga

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

October 21, 2024

From Bright Minds Biosciences

Via GlobeNewswire

MarketBeat Week in Review – 10/14 - 10/18

October 19, 2024

Via MarketBeat

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗

October 18, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock Friday? ↗

October 18, 2024

Via Benzinga

Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗

October 18, 2024

Via Benzinga

Frequently Asked Questions

Is Bright Minds Biosciences Inc. - common stock publicly traded?

Yes, Bright Minds Biosciences Inc. - common stock is publicly traded.

What exchange does Bright Minds Biosciences Inc. - common stock trade on?

Bright Minds Biosciences Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Bright Minds Biosciences Inc. - common stock?

The ticker symbol for Bright Minds Biosciences Inc. - common stock is DRUG on the Nasdaq Stock Market

What is the current price of Bright Minds Biosciences Inc. - common stock?

The current price of Bright Minds Biosciences Inc. - common stock is 77.47

When was Bright Minds Biosciences Inc. - common stock last traded?

The last trade of Bright Minds Biosciences Inc. - common stock was at 05/15/26 04:00 PM ET

What is the market capitalization of Bright Minds Biosciences Inc. - common stock?

The market capitalization of Bright Minds Biosciences Inc. - common stock is 916.81M

How many shares of Bright Minds Biosciences Inc. - common stock are outstanding?

Bright Minds Biosciences Inc. - common stock has 917M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.